CA2850245C - Pd-l1 based immunotherapy - Google Patents
Pd-l1 based immunotherapy Download PDFInfo
- Publication number
- CA2850245C CA2850245C CA2850245A CA2850245A CA2850245C CA 2850245 C CA2850245 C CA 2850245C CA 2850245 A CA2850245 A CA 2850245A CA 2850245 A CA2850245 A CA 2850245A CA 2850245 C CA2850245 C CA 2850245C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- hla
- peptide
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170574 | 2011-10-17 | ||
| DKPA201170574 | 2011-10-17 | ||
| PCT/DK2012/050386 WO2013056716A1 (en) | 2011-10-17 | 2012-10-17 | Pd-l1 based immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2850245A1 CA2850245A1 (en) | 2013-04-25 |
| CA2850245C true CA2850245C (en) | 2020-04-28 |
Family
ID=47115103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2850245A Active CA2850245C (en) | 2011-10-17 | 2012-10-17 | Pd-l1 based immunotherapy |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9669078B2 (enExample) |
| EP (2) | EP2768524B1 (enExample) |
| JP (1) | JP6259763B2 (enExample) |
| CN (2) | CN103917243B (enExample) |
| BR (1) | BR112014009526B8 (enExample) |
| CA (1) | CA2850245C (enExample) |
| CY (1) | CY1125453T1 (enExample) |
| DK (1) | DK2768524T3 (enExample) |
| ES (1) | ES2918580T3 (enExample) |
| HR (1) | HRP20220924T1 (enExample) |
| HU (1) | HUE059406T2 (enExample) |
| LT (1) | LT2768524T (enExample) |
| PL (1) | PL2768524T3 (enExample) |
| PT (1) | PT2768524T (enExample) |
| SI (1) | SI2768524T1 (enExample) |
| WO (1) | WO2013056716A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2918580T3 (es) * | 2011-10-17 | 2022-07-19 | Io Biotech Aps | Inmunoterapia basada en PD-L1 |
| TWI676636B (zh) * | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| WO2015153969A1 (en) | 2014-04-04 | 2015-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand discovery for t cell receptors |
| WO2016015095A1 (en) * | 2014-07-31 | 2016-02-04 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| PT3193917T (pt) | 2014-09-17 | 2021-10-20 | Io Biotech Aps | Composições de vacina compreendendo triptofano-2,3-dioxigenase ou fragmentos desta |
| JP6918333B2 (ja) * | 2014-09-17 | 2021-08-11 | 学校法人近畿大学 | 細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤 |
| US20160101128A1 (en) | 2014-10-10 | 2016-04-14 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonist with checkpoint inhibitors |
| ES2790823T3 (es) * | 2014-11-14 | 2020-10-29 | Liquid Genomics Inc | Uso de ARN sin células circulante para el diagnóstico y/o la monitorización de cáncer |
| DK3294329T3 (da) * | 2015-05-15 | 2020-05-04 | Reber Genetics Co Ltd | Hidtil ukendte baculovirusvektorer og fremgangsmåder til anvendelse |
| SG10202007937SA (en) * | 2015-09-02 | 2020-09-29 | Alnylam Pharmaceuticals Inc | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2017045691A1 (en) | 2015-09-16 | 2017-03-23 | Herlev Hospital | Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof |
| JP2019507180A (ja) * | 2016-03-04 | 2019-03-14 | アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ | がんに対する組合せ療法 |
| TWI840950B (zh) | 2016-03-14 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 用於降低pd-l1表現之寡核苷酸 |
| AU2017234163B2 (en) | 2016-03-15 | 2023-01-19 | Mersana Therapeutics, Inc. | NaPi2b-targeted antibody-drug conjugates and methods of use thereof |
| US20190328857A1 (en) | 2016-06-10 | 2019-10-31 | Io Biotech Aps | Calr and jak2 vaccine compositions |
| WO2017220602A1 (en) | 2016-06-21 | 2017-12-28 | Herlev Hospital | Pdl1 peptides for use in cancer vaccines |
| BR112019000015A2 (pt) | 2016-06-30 | 2019-04-24 | Oncorus, Inc. | distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| WO2018140890A1 (en) * | 2017-01-29 | 2018-08-02 | Zequn Tang | Methods of immune modulation against foreign and/or auto antigens |
| CN108503691B (zh) * | 2017-02-25 | 2021-07-23 | 复旦大学 | 一种人pd-l1蛋白高亲和性肽及其应用 |
| WO2018160538A1 (en) | 2017-02-28 | 2018-09-07 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
| JP7247097B2 (ja) * | 2017-03-17 | 2023-03-28 | バクシム アクチェンゲゼルシャフト | がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン |
| EP3713645A1 (en) * | 2017-11-24 | 2020-09-30 | IO Biotech APS | Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc) |
| US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| JP2021506883A (ja) | 2017-12-21 | 2021-02-22 | メルサナ セラピューティクス インコーポレイテッド | ピロロベンゾジアゼピン抗体結合体 |
| US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
| FR3086534B1 (fr) * | 2018-10-01 | 2020-11-06 | Univ Bordeaux | Methode pour traiter une infection par le virus de l'immunodeficience humaine |
| KR20210084546A (ko) | 2018-10-29 | 2021-07-07 | 메르사나 테라퓨틱스, 인코포레이티드 | 펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체 |
| CN109593135B (zh) * | 2018-12-29 | 2021-01-15 | 百奥赛图江苏基因生物技术有限公司 | 抗人pd-l1单克隆抗体及其应用 |
| WO2020181402A1 (zh) * | 2019-03-10 | 2020-09-17 | 胡西木 | 一种抗肿瘤多肽及其应用 |
| CN113249447A (zh) * | 2019-04-26 | 2021-08-13 | 嘉兴允英医学检验有限公司 | 一种pd-l1表达水平检测的方法和试剂盒 |
| CA3151223A1 (en) * | 2019-09-17 | 2021-03-25 | Pravin T.P. Kaumaya | Human anti-pd-l1 peptide vaccines and methods of their use |
| US20230227533A1 (en) * | 2020-04-18 | 2023-07-20 | Beijing Zeqin Biomedical Co., Ltd | Fusion peptide for treating autoimmune disease |
| CU24705B1 (es) * | 2020-10-22 | 2024-06-11 | Ct Ingenieria Genetica Biotecnologia | Antígeno quimérico que comprende el dominio extracelular de pd-l1 |
| GB202103673D0 (en) | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| CA3220007A1 (en) * | 2021-05-17 | 2022-11-24 | Wisconsin Alumni Research Foundation | Synthetic protein for inducing immune tolerance |
| KR102421307B1 (ko) * | 2021-11-19 | 2022-07-14 | 을지대학교 산학협력단 | 암 발생 및 성장 억제를 위한 신규 항암 백신 조성물 및 그를 이용한 백신화 방법 |
| EP4482962A1 (en) | 2022-02-24 | 2025-01-01 | IO Biotech ApS | Nucleotide delivery of cancer therapy |
| CN114702569B (zh) * | 2022-05-25 | 2023-01-10 | 深圳吉诺因生物科技有限公司 | Pd-l1相关疫苗及其应用 |
| WO2025043075A1 (en) * | 2023-08-24 | 2025-02-27 | The Johns Hopkins University | Methods of treating myocardial infarction, ischemia, and ischemia reperfusion injury |
| EP4527849A1 (en) | 2023-09-19 | 2025-03-26 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Hla-independent antigen binders, such as t-cell receptors, against pd-l1 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| WO2001034768A2 (en) * | 1999-11-09 | 2001-05-17 | Human Genome Sciences, Inc. | 15 human secreted proteins |
| JP2004533226A (ja) * | 2001-04-02 | 2004-11-04 | ワイス | Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用 |
| AU2002258941A1 (en) * | 2001-04-20 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| EP2206517B1 (en) * | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| CN1753912B (zh) * | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| JP2010504356A (ja) * | 2006-09-20 | 2010-02-12 | ザ ジョンズ ホプキンス ユニバーシティー | 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法 |
| WO2009026472A1 (en) | 2007-08-21 | 2009-02-26 | The General Hospital Corporation | Methods for inducing tolerance |
| EP2328920A2 (en) * | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
| EP2504028A4 (en) * | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| ES2918580T3 (es) * | 2011-10-17 | 2022-07-19 | Io Biotech Aps | Inmunoterapia basada en PD-L1 |
-
2012
- 2012-10-17 ES ES12780408T patent/ES2918580T3/es active Active
- 2012-10-17 WO PCT/DK2012/050386 patent/WO2013056716A1/en not_active Ceased
- 2012-10-17 HU HUE12780408A patent/HUE059406T2/hu unknown
- 2012-10-17 DK DK12780408.6T patent/DK2768524T3/da active
- 2012-10-17 US US14/352,407 patent/US9669078B2/en active Active
- 2012-10-17 HR HRP20220924TT patent/HRP20220924T1/hr unknown
- 2012-10-17 PT PT127804086T patent/PT2768524T/pt unknown
- 2012-10-17 BR BR112014009526A patent/BR112014009526B8/pt active IP Right Grant
- 2012-10-17 EP EP12780408.6A patent/EP2768524B1/en active Active
- 2012-10-17 CN CN201280050948.7A patent/CN103917243B/zh active Active
- 2012-10-17 EP EP22163851.3A patent/EP4079319A1/en active Pending
- 2012-10-17 CA CA2850245A patent/CA2850245C/en active Active
- 2012-10-17 JP JP2014536116A patent/JP6259763B2/ja active Active
- 2012-10-17 SI SI201232003T patent/SI2768524T1/sl unknown
- 2012-10-17 CN CN202110437930.3A patent/CN113444165A/zh active Pending
- 2012-10-17 LT LTEPPCT/DK2012/050386T patent/LT2768524T/lt unknown
- 2012-10-17 PL PL12780408.6T patent/PL2768524T3/pl unknown
-
2022
- 2022-08-02 CY CY20221100528T patent/CY1125453T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT2768524T (lt) | 2022-07-25 |
| CN103917243B (zh) | 2021-05-11 |
| JP2014534202A (ja) | 2014-12-18 |
| US9669078B2 (en) | 2017-06-06 |
| DK2768524T3 (da) | 2022-07-04 |
| JP6259763B2 (ja) | 2018-01-10 |
| WO2013056716A1 (en) | 2013-04-25 |
| CN103917243A (zh) | 2014-07-09 |
| BR112014009526B8 (pt) | 2023-01-17 |
| CA2850245A1 (en) | 2013-04-25 |
| PT2768524T (pt) | 2022-07-05 |
| EP4079319A1 (en) | 2022-10-26 |
| SI2768524T1 (sl) | 2022-09-30 |
| CN113444165A (zh) | 2021-09-28 |
| BR112014009526A2 (pt) | 2017-05-09 |
| EP2768524B1 (en) | 2022-05-04 |
| EP2768524A1 (en) | 2014-08-27 |
| CY1125453T1 (el) | 2025-05-09 |
| HRP20220924T1 (hr) | 2022-10-28 |
| PL2768524T3 (pl) | 2022-09-19 |
| ES2918580T3 (es) | 2022-07-19 |
| HUE059406T2 (hu) | 2022-11-28 |
| BR112014009526B1 (pt) | 2021-07-13 |
| US20140242101A1 (en) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2850245C (en) | Pd-l1 based immunotherapy | |
| US12233103B2 (en) | Indoleamine 2,3-dioxygenase based immunotherapy | |
| US11878053B2 (en) | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof | |
| IL257940B (en) | Vaccines that include the CC motif. Chemokine 22 or fragments thereof | |
| HK40074521A (en) | Pd-l1 based immunotherapy | |
| HK1247114A1 (en) | Indoleamine 2, 3-dioxygenase based immunotherapy | |
| WO2013060328A1 (en) | Ikb based immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171017 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240904 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240904 |